NL-OMON48429已完成不适用
An open-label, exploratory, randomised, three-period, six-sequence single dose crossover study comparing the safety, tolerability and pharmacokinetic profile of a new and marketed flurbiprofen (8.75 mg) spray in healthy male/female subjects under fasting conditions. - Safety, tolerability and PK study of a new flurbiprofen 8.75 mg spray
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 16
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Only subjects to whom all of the following conditions apply will be included:
- •1. Subject has provided written informed consent.
- •2. Subject is male or female and aged: * 18 years * 55 years.
- •3. Subjects with a Body Mass Index (BMI) of * 18.5 and * 30kg/m2.
- •4. Subject is healthy with no clinically significant abnormal findings as determined by medical history, physical examination, vital signs, laboratory tests and echocardiogram (ECG) at screening.
- •5. Subjects with normal oral mucosa (score of 0 on the WHO Oral Mucositis Guideline).
- •6. Female subjects of child bearing potential willing to use a highly effective method of contraception throughout the study.
- •OR Female subjects who are post-menopausal or permanently sterilised.
- •7. Subjects who are willing to abstain from food and drinks that contains either caffeine, xanthine, grapefruit (including marmalade and juice) and poppy seeds for 48 hours prior to the first drug administration until the end of the last treatment period.
- •8. Subjects who are willing to abstain from strenuous exercise for 72 hours prior to the first drug administration until the end of the
- •last treatment period.
- •9. Subject is willing to comply with all study procedures and is available for the duration of the study.
排除标准
- •Subjects to whom any of the following conditions apply must be excluded:
- •1. Subject has a current or previous clinically significant medical history, as determined by the Investigator, including, but not limited to cardiovascular, hepatic, renal, respiratory, gastro-intestinal, neurological, metabolic, ear, nose and throat (ENT), dental and psychiatric disorders.
- •2. Subject has any condition that may currently interfere with the absorption, distribution, metabolism or excretion of drugs.
- •3. Subject has any taste disorder.
- •4. Subject has a known history of previous allergy, anaphylactic reactions or intolerance related to treatment with flurbiprofen, ibuprofen or other NSAIDs, codeine or the excipients of the test or reference IMPs.
- •5. Subject is a current smoker (including e-cigarettes) or ex-smoker who has smoked or used nicotine-containing products within 3 years of screening.
- •6. Subject has a history of drug or alcohol abuse according to the DSM-IV classification or a positive test for drugs of abuse and/or alcohol at screening.
- •7. Subject has used prescription or non-prescription drugs, including NSAIDs, vitamins, herbal and dietary supplements (with the exception of the continued use of HRT and contraceptives) in the 14 days (or 5 half-lives of the drug, whichever is longer) before first drug administration.
- •8. Subject has donated 450 mL (or more) blood, including blood products, or has significant loss of blood in the 90 days prior to screening or at any time during the study, except as required by this protocol.
- •9. Subject has known human immunodeficiency virus (HIV) positive status, or a positive viral serology screen (Hepatitis B surface antigen (HBsAg), Hepatitis C antibody, HIV tests).
- •10. Female subject who is pregnant as confirmed by a positive pregnancy test or is lactating.
- •11. Subject has received an investigational product, or participation in another trial involving a marketed or investigational drug in the 30 days prior to first drug administration.
- •12. Subject who is an employee at the Clinical Unit or is a partner or first degree relative of the Investigator.
- •13. Subject fails to satisfy the investigator of fitness to participate for any other reason.
研究者
相似试验
招募中
1 期
A Phase 3 open-label, controlled, randomised, multi-centre trial comparing imlifidase and standard-of-care with standard-of-care alone in the treatment of severe anti-GBM antibody disease (Goodpasture disease)Anti-GBM antibody disease (Goodpasture disease)MedDRA version: 22.0Level: LLTClassification code: 10081982Term: Anti-GBM disease Class: 10038359CTIS2022-500121-33-01Hansa Biopharma AB51
招募中
3 期
Study of efficacy of capmatinib in comparison with standard of care docetaxel as a second or third line therapy in participants with non-small cell lung cancers harboring MET exon 14 skipping mutation.CTRI/2020/09/027575ovartis Healthcare Pvt Ltd
进行中（未招募）
1 期
Study of efficacy of capmatinib in comparison with standard of care docetaxel as a second or third line therapy in participants with non-small cell lung cancers harboring MET exon 14 skipping mutation.EUCTR2020-001578-31-NLovartis Pharma AG90
已完成
3 期
A phase III, randomized, controlled, open-label, multicenter, global study of capmatinib versus SoC docetaxel chemotherapy in previously treated patients with EGFR wt, ALK negative, locally advanced or metastatic (stage IIIB/IIIC or IV) NSCLC harboring MET exon 14 skipping mutation (MET*ex14)non small cell lung cancer with a C-MET mutation10038666NL-OMON52922ovartis4
进行中（未招募）
1 期
Study of efficacy of capmatinib in comparison with standard of care docetaxel as a second or third line therapy in participants with non-small cell lung cancers harboring MET exon 14 skipping mutation.EUCTR2020-001578-31-ITOVARTIS PHARMA AG90